Paul J Wang, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Dominican Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G86914 · Current
Licensed to practise in California · since 2003 · expires 2028-08-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$104,344
Medicare paid this office $104,344 for 511 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 25 | $19,689 | $788 |
| Return visit (30+ min) | 118 | $10,290 | $80 |
| Return visit (30+ min) | 74 | $9,218 | $114 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $8,297 | $691 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $5,273 | $439 |
See all 22 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 25 | $19,689 | $788 |
| Return visit (30+ min) | 118 | $10,290 | $80 |
| Return visit (30+ min) | 74 | $9,218 | $114 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $8,297 | $691 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $5,273 | $439 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 12 | $3,811 | $254 |
| Short return visit (20+ min) | 45 | $3,574 | $79 |
| New patient visit (45+ min) | 33 | $3,512 | $106 |
| Short return visit (20+ min) | 58 | $2,854 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,331 | $69 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 76 | $2,053 | $22 |
| Programming of dual lead pacemaker system | 63 | $2,008 | $29 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,963 | $115 |
| New patient visit (45+ min) | 11 | $1,722 | $157 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 43 | $1,373 | $26 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,056 | $44 |
| New patient visit (30+ min) | 15 | $859 | $57 |
| Programming of dual lead implantable defibrillator system | 16 | $850 | $47 |
| Short return visit | 14 | $665 | $47 |
| Programming of multiple lead implantable defibrillator system | 13 | $599 | $40 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $356 | $20 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 14 | $254 | $18 |
Procedures Medicare counted
| Pacemaker insertion or repair | 27 | More than 77% of doctors who do this |
Who their Medicare patients are
511 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 38% · Also on Medicaid 17% · Health risk score 1.65. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 75% · Coronary heart disease 48% · Heart failure 46% · Chronic kidney disease 34% · Diabetes 28% · Cancer 19% · COPD 15% · Depression 14% · Stroke 14% · Dementia 7%.
The office billed $734,873, Medicare allowed $137,756 and paid $104,344; for 947 services of 64 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 511 | 947 | 77 | 1.65 | $734,873 | $104,344 |
| 2023 | 923 | 1,464 | 77 | 1.87 | $712,499 | $104,935 |
| 2022 | 610 | 1,004 | 76 | 1.73 | $786,094 | $118,153 |
| 2021 | 548 | 920 | 75 | 1.59 | $777,985 | $119,902 |
| 2020 | 764 | 1,253 | 75 | 1.85 | $612,991 | $100,994 |
| 2019 | 828 | 1,506 | 76 | 1.78 | $725,876 | $141,323 |
| 2018 | 904 | 1,623 | 75 | 1.74 | $655,343 | $140,637 |
| 2017 | 1,062 | 2,326 | 75 | 1.70 | $881,158 | $190,649 |
| 2016 | 1,366 | 2,757 | 74 | 1.94 | $867,300 | $180,265 |
| 2015 | 1,019 | 2,248 | 74 | 1.78 | $768,052 | $164,030 |
| 2014 | 1,735 | 3,486 | 73 | 1.73 | $851,243 | $182,794 |
| 2013 | 1,630 | 3,311 | 74 | 1.82 | $782,187 | $162,823 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 21 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 25 | $20,550 | $822 |
| Return visit (30+ min) | 170 | $15,785 | $86 |
| New patient visit (45+ min) | 54 | $5,892 | $109 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 96 | $3,417 | $26 |
| Short return visit (20+ min) | 57 | $3,294 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 341 | $2,962 | $7 |
| New patient visit (60+ min) | 16 | $2,338 | $146 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 50 | $2,247 | $34 |
| Programming of dual lead pacemaker system | 67 | $2,161 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,824 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 32 | $1,761 | $45 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 72 | $1,747 | $23 |
| Long return visit (40+ min) | 13 | $1,656 | $127 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,426 | $71 |
| Short return visit | 48 | $1,401 | $29 |
| Programming of multiple lead implantable defibrillator system | 20 | $1,309 | $57 |
| New patient visit (30+ min) | 14 | $985 | $70 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 16 | $601 | $23 |
| New patient visit (15+ min) | 15 | $481 | $32 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $377 | $29 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 15 | $325 | $22 |
2022: 17 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 19 | $18,547 | $976 |
| Return visit (30+ min) | 153 | $14,374 | $86 |
| Insertion of implantable defibrillator system | 13 | $10,737 | $826 |
| New patient visit (60+ min) | 53 | $8,977 | $169 |
| New patient visit (45+ min) | 56 | $6,286 | $112 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $6,088 | $468 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 12 | $4,904 | $409 |
| Short return visit (20+ min) | 74 | $4,078 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,380 | $61 |
| Long return visit (40+ min) | 20 | $2,592 | $130 |
| New patient visit (30+ min) | 25 | $1,822 | $73 |
| Programming of dual lead pacemaker system | 48 | $1,726 | $35 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 48 | $1,346 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 126 | $1,033 | $7 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $763 | $29 |
| Programming of multiple lead implantable defibrillator system | 12 | $748 | $53 |
| Short return visit | 27 | $732 | $27 |
2021: 19 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 24 | $23,692 | $987 |
| Return visit (30+ min) | 129 | $11,608 | $82 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 33 | $8,639 | $262 |
| New patient visit (60+ min) | 46 | $8,080 | $176 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 13 | $5,569 | $371 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $4,714 | $66 |
| Short return visit (20+ min) | 82 | $4,689 | $56 |
| Removal and replacement of multiple lead defibrillator | 12 | $4,423 | $369 |
| New patient visit (45+ min) | 31 | $3,562 | $115 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 29 | $3,346 | $115 |
| Long return visit (40+ min) | 14 | $1,708 | $122 |
| Programming of dual lead pacemaker system | 34 | $1,259 | $35 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,106 | $92 |
| New patient visit (30+ min) | 13 | $1,006 | $77 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 115 | $947 | $8 |
| Programming of multiple lead implantable defibrillator system | 15 | $944 | $59 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 29 | $763 | $25 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $495 | $35 |
| Short return visit | 16 | $458 | $29 |
2020: 24 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $16,205 | $1,013 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 19 | $9,102 | $479 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 22 | $5,832 | $265 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,549 | $68 |
| Short return visit (20+ min) | 85 | $3,487 | $41 |
| Return visit (30+ min) | 46 | $2,923 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 278 | $2,625 | $8 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $2,605 | $137 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 66 | $2,478 | $29 |
| Telephone medical discussion with physician, 11-20 minutes | 47 | $2,197 | $46 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 45 | $2,032 | $34 |
| Long return visit (40+ min) | 18 | $1,756 | $98 |
| New patient visit (60+ min) | 13 | $1,704 | $131 |
| Programming of dual lead pacemaker system | 42 | $1,525 | $32 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,300 | $118 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 40 | $1,143 | $24 |
| Programming of dual lead implantable defibrillator system | 13 | $1,046 | $55 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,032 | $74 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $1,021 | $36 |
| New patient visit (30+ min) | 14 | $760 | $54 |
| Telephone medical discussion with physician, 5-10 minutes | 32 | $742 | $23 |
| New patient visit (15+ min) | 16 | $699 | $44 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $382 | $25 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 12 | $137 | $11 |
2019: 26 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 18 | $17,793 | $988 |
| Insertion of implantable defibrillator system | 19 | $15,644 | $823 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 25 | $11,413 | $457 |
| Return visit (30+ min) | 132 | $9,406 | $65 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $7,018 | $413 |
| Programming of dual lead pacemaker system | 135 | $6,196 | $34 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 23 | $6,000 | $261 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $5,658 | $66 |
| Short return visit (20+ min) | 122 | $5,522 | $42 |
| New patient visit (60+ min) | 34 | $4,118 | $121 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 66 | $3,970 | $42 |
| Programming of multiple lead implantable defibrillator system | 35 | $2,894 | $58 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $2,536 | $133 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 75 | $2,409 | $28 |
| Programming of dual lead implantable defibrillator system | 33 | $2,190 | $52 |
| New patient visit (30+ min) | 29 | $1,988 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 200 | $1,727 | $8 |
| Long return visit (40+ min) | 16 | $1,615 | $101 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,272 | $91 |
| Return visit (30+ min) | 14 | $1,226 | $88 |
| New patient visit (15+ min) | 22 | $968 | $44 |
| Short return visit (20+ min) | 13 | $822 | $59 |
| Programming of multiple lead pacemaker system | 14 | $799 | $40 |
| Programming of single lead implantable defibrillator system | 11 | $474 | $40 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $392 | $25 |
| Programming of single lead pacemaker system | 12 | $361 | $28 |
2018: 25 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $15,586 | $974 |
| Insertion of implantable defibrillator system | 19 | $15,172 | $799 |
| Short return visit (20+ min) | 303 | $12,584 | $40 |
| New patient visit (60+ min) | 73 | $9,534 | $131 |
| Return visit (30+ min) | 112 | $9,113 | $70 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $6,917 | $407 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 22 | $6,280 | $285 |
| Programming of dual lead pacemaker system | 140 | $5,919 | $32 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,291 | $441 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 63 | $3,566 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,465 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 35 | $3,144 | $90 |
| Long return visit (40+ min) | 31 | $3,030 | $98 |
| Programming of multiple lead implantable defibrillator system | 41 | $2,717 | $54 |
| Programming of dual lead implantable defibrillator system | 45 | $2,683 | $48 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 15 | $1,977 | $132 |
| Return visit (30+ min) | 15 | $1,832 | $87 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 48 | $1,539 | $26 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 157 | $1,351 | $7 |
| New patient visit (15+ min) | 37 | $1,238 | $33 |
| New patient visit (30+ min) | 17 | $1,155 | $68 |
| Short return visit (20+ min) | 14 | $766 | $45 |
| Programming of multiple lead pacemaker system | 11 | $432 | $36 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $156 | $14 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $154 | $11 |
2017: 30 services
| Short return visit (20+ min) | 490 | $21,776 | $40 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 22 | $21,441 | $975 |
| Insertion of implantable defibrillator system | 20 | $16,755 | $798 |
| Programming of dual lead pacemaker system | 205 | $11,442 | $33 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 32 | $10,628 | $332 |
| New patient visit (60+ min) | 51 | $7,523 | $148 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 87 | $7,465 | $57 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $7,350 | $459 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $7,322 | $407 |
| Return visit (30+ min) | 92 | $6,106 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $5,252 | $64 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 14 | $5,155 | $368 |
| Programming of multiple lead implantable defibrillator system | 60 | $4,691 | $52 |
| Programming of dual lead implantable defibrillator system | 55 | $4,495 | $49 |
| Long return visit (40+ min) | 43 | $4,099 | $95 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 26 | $3,389 | $130 |
| New patient visit (15+ min) | 96 | $3,370 | $35 |
| New patient visit (45+ min) | 29 | $3,259 | $112 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 74 | $2,936 | $29 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 28 | $2,512 | $90 |
| Programming of multiple lead pacemaker system | 18 | $1,646 | $41 |
| Short return visit (20+ min) | 23 | $1,268 | $47 |
| Programming of single lead pacemaker system | 24 | $859 | $27 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 18 | $793 | $40 |
| New patient visit (15+ min) | 12 | $719 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 33 | $564 | $17 |
| New patient visit (30+ min) | 11 | $543 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 55 | $425 | $8 |
| Programming of cardiac rhythm monitor system | 12 | $308 | $19 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 22 | $233 | $11 |
2016: 27 services
| Short return visit (20+ min) | 533 | $26,067 | $41 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 22 | $21,425 | $974 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 36 | $12,341 | $343 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 15 | $10,892 | $726 |
| Insertion of implantable defibrillator system | 13 | $10,469 | $805 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 20 | $9,275 | $464 |
| Programming of dual lead pacemaker system | 167 | $9,247 | $34 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 67 | $7,114 | $60 |
| New patient visit (15+ min) | 151 | $6,186 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $5,553 | $64 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 14 | $5,113 | $365 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 559 | $5,057 | $8 |
| Return visit (30+ min) | 69 | $4,764 | $67 |
| Programming of multiple lead implantable defibrillator system | 44 | $3,805 | $55 |
| Programming of dual lead implantable defibrillator system | 52 | $3,760 | $50 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 23 | $2,994 | $130 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 40 | $1,597 | $30 |
| New patient visit (15+ min) | 27 | $1,441 | $53 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,386 | $87 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 11 | $1,114 | $101 |
| Programming of single lead pacemaker system | 24 | $1,079 | $29 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 45 | $973 | $18 |
| Short return visit (20+ min) | 13 | $957 | $48 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 22 | $849 | $37 |
| Programming of multiple lead pacemaker system | 13 | $814 | $41 |
| Short return visit | 36 | $795 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $265 | $24 |
2015: 22 services
| Short return visit (20+ min) | 476 | $23,948 | $41 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 21 | $20,321 | $968 |
| Insertion of implantable defibrillator system | 18 | $14,507 | $806 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 27 | $9,139 | $338 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 18 | $8,251 | $458 |
| Programming of dual lead pacemaker system | 149 | $7,860 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $6,093 | $64 |
| New patient visit (15+ min) | 140 | $5,794 | $41 |
| Return visit (30+ min) | 78 | $5,713 | $66 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 15 | $5,417 | $361 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 50 | $4,975 | $59 |
| Programming of dual lead implantable defibrillator system | 56 | $4,429 | $47 |
| Programming of multiple lead implantable defibrillator system | 58 | $4,397 | $52 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 11 | $3,973 | $361 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 255 | $2,379 | $8 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 16 | $2,082 | $130 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,949 | $89 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 52 | $1,270 | $18 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 28 | $1,227 | $38 |
| Programming of single lead pacemaker system | 31 | $1,127 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $1,029 | $29 |
| Short return visit | 39 | $832 | $21 |
2014: 28 services
| Short return visit (20+ min) | 514 | $27,760 | $40 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $17,377 | $965 |
| Insertion of implantable defibrillator system | 16 | $12,732 | $796 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 30 | $10,800 | $337 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 14 | $10,137 | $724 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 962 | $9,544 | $8 |
| Programming of dual lead pacemaker system | 191 | $9,300 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $8,519 | $64 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 18 | $8,275 | $460 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 71 | $6,827 | $56 |
| Programming of multiple lead implantable defibrillator system | 77 | $5,887 | $52 |
| Removal and replacement of multiple lead defibrillator | 15 | $5,493 | $366 |
| New patient visit (15+ min) | 133 | $5,428 | $41 |
| Programming of dual lead implantable defibrillator system | 61 | $4,855 | $49 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 11 | $4,393 | $399 |
| Return visit (30+ min) | 35 | $2,250 | $62 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 25 | $2,232 | $89 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 16 | $2,208 | $130 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 46 | $1,936 | $37 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 34 | $1,464 | $29 |
| External shock to heart to regulate heart beat | 12 | $1,326 | $110 |
| Programming of single lead pacemaker system | 30 | $1,164 | $26 |
| Short return visit | 45 | $1,048 | $22 |
| Programming of multiple lead pacemaker system | 16 | $857 | $37 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 40 | $849 | $18 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $625 | $35 |
| Programming of single lead implantable defibrillator system | 12 | $575 | $38 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $304 | $23 |
2013: 26 services
| Short return visit (20+ min) | 432 | $24,180 | $39 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 18 | $16,156 | $850 |
| Insertion of implantable defibrillator system | 17 | $13,087 | $770 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $11,216 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 831 | $8,340 | $7 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 24 | $7,745 | $323 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 64 | $7,224 | $56 |
| Programming of dual lead pacemaker system | 165 | $6,517 | $30 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 15 | $5,717 | $381 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,281 | $440 |
| New patient visit (15+ min) | 131 | $5,168 | $39 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,543 | $116 |
| Programming of dual lead implantable defibrillator system | 56 | $4,050 | $48 |
| Programming of multiple lead implantable defibrillator system | 61 | $3,956 | $51 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 67 | $3,083 | $39 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 104 | $2,241 | $17 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 12 | $1,487 | $124 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 30 | $1,377 | $28 |
| Return visit (30+ min) | 16 | $1,038 | $61 |
| Programming of single lead pacemaker system | 27 | $898 | $27 |
| Short return visit | 39 | $820 | $21 |
| Programming of single lead implantable defibrillator system | 17 | $613 | $34 |
| Programming of multiple lead pacemaker system | 11 | $465 | $39 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 20 | $458 | $22 |
| Other cardiovascular service or procedure | 12 | $302 | $23 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $249 | $23 |
Medicaid work
$3,349 in 2023
Medicaid paid $3,349 for 379 billed services this clinician did in 2023, up to 180 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 379 | $3,349 |
| 2023 | 379 | 1 | 180 | $3,349 |
| 2022 | 110 | 1 | 65 | $981 |
| 2021 | 89 | 1 | 42 | $704 |
| 2020 | 292 | 1 | 107 | $2,860 |
| 2019 | 109 | 1 | 36 | $1,116 |
| 2018 | 87 | 1 | 73 | $843 |
See the largest Medicaid services in earlier years
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 110 | $981 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 89 | $704 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 292 | $2,860 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 109 | $1,116 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 87 | $843 |
Drugs they prescribed that Part D paid
$588,035
Pharmacies billed $588,035 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,068) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
642 generic and 426 brand-name prescriptions · $588,035 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 290 | $377,986 | $1,303 |
| Xarelto | 71 | $91,468 | $1,288 |
| Multaq | 44 | $86,249 | $1,960 |
| Enoxaparin | 85 | $5,033 | $59 |
| Flecainide Acetate | 77 | $5,022 | $65 |
See all 15 drugs
| Eliquis | 290 | $377,986 | $1,303 |
| Xarelto | 71 | $91,468 | $1,288 |
| Multaq | 44 | $86,249 | $1,960 |
| Enoxaparin | 85 | $5,033 | $59 |
| Flecainide Acetate | 77 | $5,022 | $65 |
| Dofetilide | 25 | $3,205 | $128 |
| Amiodarone | 74 | $2,047 | $28 |
| Metoprolol | 93 | $1,878 | $20 |
| Diltiazem 24hr Er (Cd) | 34 | $1,549 | $46 |
| Sotalol | 27 | $894 | $33 |
| Sucralfate | 29 | $892 | $31 |
| Digoxin | 16 | $608 | $38 |
| Propafenone | 18 | $607 | $34 |
| Pantoprazole | 39 | $296 | $8 |
| Metoprolol | 31 | $172 | $6 |
Year by year
| 2024 | 1,068 | 243 | 0% (0) | 40% | $588,035 |
| 2023 | 1,000 | 234 | 0% (0) | 45% | $638,430 |
| 2022 | 1,031 | 239 | 0% (0) | 48% | $638,005 |
| 2021 | 1,005 | 215 | 0% (0) | 42% | $510,068 |
| 2020 | 1,364 | 262 | 0% (0) | 46% | $649,723 |
| 2019 | 1,766 | 298 | None | None | $658,827 |
| 2018 | 2,046 | 334 | 0% (0) | 43% | $580,969 |
| 2017 | 2,060 | 330 | None | None | $494,918 |
| 2016 | 1,815 | 282 | None | 42% | $402,704 |
| 2015 | 1,449 | 247 | None | 37% | $235,980 |
| 2014 | 1,296 | 226 | None | 28% | $156,617 |
| 2013 | 1,165 | 191 | None | 23% | $112,683 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Eliquis | 262 | $365,796 | $1,396 |
| Xarelto | 88 | $116,292 | $1,321 |
| Multaq | 68 | $113,915 | $1,675 |
| Enoxaparin | 71 | $5,533 | $78 |
| Flecainide Acetate | 64 | $3,466 | $54 |
| Dofetilide | 24 | $3,393 | $141 |
| Metoprolol | 80 | $2,537 | $32 |
| Amiodarone | 61 | $2,424 | $40 |
| Diltiazem 24hr Er (Cd) | 28 | $2,306 | $82 |
| Sucralfate | 30 | $1,040 | $35 |
| Cartia Xt | 12 | $713 | $59 |
| Sotalol | 18 | $621 | $35 |
| Metoprolol | 36 | $503 | $14 |
| Digoxin | 11 | $395 | $36 |
| Carvedilol | 14 | $234 | $17 |
| Pantoprazole | 27 | $150 | $6 |
2022: 17 drugs
| Eliquis | 254 | $315,686 | $1,243 |
| Multaq | 122 | $176,831 | $1,449 |
| Xarelto | 79 | $86,624 | $1,097 |
| Pradaxa | 17 | $18,524 | $1,090 |
| Dofetilide | 28 | $7,141 | $255 |
| Flecainide Acetate | 63 | $6,400 | $102 |
| Enoxaparin | 67 | $5,586 | $83 |
| Metoprolol | 83 | $2,905 | $35 |
| Amiodarone | 59 | $2,855 | $48 |
| Mexiletine | 11 | $2,018 | $183 |
| Diltiazem 24hr Er (Cd) | 42 | $1,963 | $47 |
| Sucralfate | 23 | $1,329 | $58 |
| Metoprolol | 37 | $576 | $16 |
| Carvedilol | 22 | $407 | $19 |
| Pantoprazole | 22 | $186 | $8 |
| Bisoprolol | 15 | $186 | $12 |
| Lisinopril | 12 | $40 | $3 |
2021: 18 drugs
| Eliquis | 211 | $259,917 | $1,232 |
| Multaq | 79 | $104,876 | $1,328 |
| Xarelto | 67 | $78,419 | $1,170 |
| Pradaxa | 26 | $24,241 | $932 |
| Dofetilide | 41 | $8,774 | $214 |
| Flecainide Acetate | 74 | $7,120 | $96 |
| Enoxaparin | 62 | $4,950 | $80 |
| Propafenone Hcl Er | 13 | $4,047 | $311 |
| Diltiazem 24hr Er (Cd) | 58 | $3,597 | $62 |
| Amiodarone | 75 | $3,062 | $41 |
| Mexiletine | 12 | $2,531 | $211 |
| Metoprolol | 67 | $2,491 | $37 |
| Sucralfate | 29 | $1,255 | $43 |
| Bisoprolol | 18 | $496 | $28 |
| Diltiazem | 12 | $413 | $34 |
| Metoprolol | 36 | $274 | $8 |
| Carvedilol | 17 | $243 | $14 |
| Pantoprazole | 23 | $169 | $7 |
2020: 18 drugs
| Eliquis | 349 | $319,303 | $915 |
| Multaq | 83 | $131,106 | $1,580 |
| Xarelto | 119 | $119,010 | $1,000 |
| Pradaxa | 29 | $28,290 | $976 |
| Flecainide Acetate | 115 | $9,930 | $86 |
| Dofetilide | 33 | $8,834 | $268 |
| Diltiazem 24hr Er (Cd) | 87 | $6,110 | $70 |
| Mexiletine | 15 | $4,366 | $291 |
| Metoprolol | 129 | $3,803 | $29 |
| Enoxaparin | 42 | $3,626 | $86 |
| Amiodarone | 104 | $2,459 | $24 |
| Sucralfate | 24 | $957 | $40 |
| Metoprolol | 45 | $341 | $8 |
| Carvedilol | 24 | $287 | $12 |
| Pantoprazole | 23 | $251 | $11 |
| Cartia Xt | 14 | $166 | $12 |
| Amlodipine Besylate | 11 | $92 | $8 |
| Lisinopril | 12 | $29 | $2 |
2019: 23 drugs
| Eliquis | 443 | $312,476 | $705 |
| Multaq | 102 | $129,379 | $1,268 |
| Xarelto | 129 | $101,743 | $789 |
| Pradaxa | 56 | $39,735 | $710 |
| Dofetilide | 33 | $17,907 | $543 |
| Flecainide Acetate | 125 | $10,090 | $81 |
| Propafenone Hcl Er | 28 | $10,022 | $358 |
| Enoxaparin | 74 | $7,655 | $103 |
| Diltiazem 24hr Er (Cd) | 93 | $6,308 | $68 |
| Metoprolol | 144 | $5,082 | $35 |
| Amiodarone | 112 | $2,035 | $18 |
| Cartia Xt | 50 | $1,402 | $28 |
| Sucralfate | 27 | $962 | $36 |
| Sotalol | 26 | $837 | $32 |
| Carvedilol | 50 | $520 | $10 |
| Metoprolol | 65 | $359 | $6 |
| Diltiazem | 19 | $303 | $16 |
| Warfarin | 13 | $247 | $19 |
| Lisinopril | 28 | $174 | $6 |
| Pantoprazole | 17 | $161 | $9 |
| Atorvastatin | 16 | $155 | $10 |
| Furosemide | 11 | $57 | $5 |
| Hydrochlorothiazide | 13 | $18 | $1 |
2018: 26 drugs
| Eliquis | 465 | $249,899 | $537 |
| Multaq | 131 | $114,796 | $876 |
| Xarelto | 153 | $98,929 | $647 |
| Pradaxa | 83 | $47,084 | $567 |
| Dofetilide | 41 | $21,549 | $526 |
| Flecainide Acetate | 154 | $10,518 | $68 |
| Propafenone Hcl Er | 19 | $7,864 | $414 |
| Enoxaparin | 60 | $5,264 | $88 |
| Diltiazem 24hr Er (Cd) | 85 | $4,948 | $58 |
| Metoprolol | 157 | $3,215 | $20 |
| Amiodarone | 135 | $3,138 | $23 |
| Cartia Xt | 96 | $3,003 | $31 |
| Sotalol | 33 | $724 | $22 |
| Carvedilol | 74 | $590 | $8 |
| Digoxin | 18 | $517 | $29 |
| Sucralfate | 17 | $481 | $28 |
| Acebutolol | 16 | $416 | $26 |
| Metoprolol | 80 | $349 | $4 |
| Warfarin | 17 | $245 | $14 |
| Diltiazem | 13 | $216 | $17 |
| Amlodipine Besylate | 14 | $155 | $11 |
| Atenolol | 24 | $151 | $6 |
| Pantoprazole | 14 | $80 | $6 |
| Lisinopril | 25 | $76 | $3 |
| Cephalexin | 12 | $73 | $6 |
| Hydrochlorothiazide | 14 | $19 | $1 |
2017: 32 drugs
| Eliquis | 392 | $190,292 | $485 |
| Multaq | 135 | $119,604 | $886 |
| Xarelto | 109 | $60,259 | $553 |
| Pradaxa | 67 | $35,974 | $537 |
| Dofetilide | 37 | $25,836 | $698 |
| Flecainide Acetate | 139 | $12,420 | $89 |
| Diltiazem 24hr Er | 100 | $5,647 | $56 |
| Propafenone Hcl Er | 15 | $5,257 | $350 |
| Mexiletine | 16 | $5,135 | $321 |
| Enoxaparin | 50 | $4,939 | $99 |
| Amiodarone | 184 | $3,982 | $22 |
| Cartia Xt | 107 | $2,834 | $26 |
| Metoprolol | 104 | $1,882 | $18 |
| Digox | 17 | $1,052 | $62 |
| Digoxin | 25 | $837 | $33 |
| Sucralfate | 21 | $618 | $29 |
| Diltiazem | 39 | $566 | $15 |
| Metoprolol | 70 | $517 | $7 |
| Carvedilol | 62 | $404 | $7 |
| Potassium Chloride | 19 | $397 | $21 |
| Sotalol | 20 | $381 | $19 |
| Acebutolol | 16 | $374 | $23 |
| Warfarin | 28 | $353 | $13 |
| Digitek | 11 | $228 | $21 |
| Furosemide | 31 | $169 | $5 |
| Pantoprazole | 18 | $159 | $9 |
| Amlodipine Besylate | 17 | $141 | $8 |
| Atenolol | 17 | $84 | $5 |
| Cephalexin | 13 | $77 | $6 |
| Simvastatin | 11 | $50 | $5 |
| Hydrochlorothiazide | 16 | $35 | $2 |
| Lisinopril | 15 | $25 | $2 |
2016: 28 drugs
| Multaq | 138 | $116,137 | $842 |
| Eliquis | 233 | $99,701 | $428 |
| Xarelto | 112 | $56,604 | $505 |
| Pradaxa | 68 | $39,219 | $577 |
| Tikosyn | 51 | $28,952 | $568 |
| Propafenone Hcl Er | 20 | $8,455 | $423 |
| Enoxaparin | 41 | $7,157 | $175 |
| Flecainide Acetate | 131 | $5,408 | $41 |
| Diltiazem 24hr Er | 103 | $5,360 | $52 |
| Amiodarone | 153 | $3,967 | $26 |
| Metoprolol | 118 | $2,608 | $22 |
| Cartia Xt | 68 | $1,804 | $27 |
| Mexiletine | 14 | $1,570 | $112 |
| Digoxin | 24 | $980 | $41 |
| Metoprolol | 81 | $550 | $7 |
| Sucralfate | 20 | $505 | $25 |
| Diltiazem | 27 | $494 | $18 |
| Klor-Con 10 | 16 | $449 | $28 |
| Acebutolol | 17 | $417 | $25 |
| Sotalol | 21 | $366 | $17 |
| Sotalol Af | 11 | $345 | $31 |
| Atorvastatin | 20 | $288 | $14 |
| Warfarin | 33 | $276 | $8 |
| Carvedilol | 32 | $272 | $9 |
| Furosemide | 41 | $187 | $5 |
| Losartan | 19 | $141 | $7 |
| Pantoprazole | 16 | $127 | $8 |
| Amlodipine Besylate | 15 | $85 | $6 |
2015: 27 drugs
| Multaq | 106 | $62,001 | $585 |
| Eliquis | 98 | $39,766 | $406 |
| Xarelto | 87 | $35,067 | $403 |
| Pradaxa | 56 | $23,168 | $414 |
| Tikosyn | 47 | $22,702 | $483 |
| Propafenone Hcl Er | 28 | $10,864 | $388 |
| Enoxaparin | 47 | $9,959 | $212 |
| Flecainide Acetate | 142 | $6,800 | $48 |
| Amiodarone | 134 | $4,005 | $30 |
| Diltiazem 24hr Er | 36 | $3,611 | $100 |
| Metoprolol | 119 | $2,233 | $19 |
| Cartia Xt | 67 | $2,153 | $32 |
| Digoxin | 28 | $1,212 | $43 |
| Sucralfate | 22 | $879 | $40 |
| Diltiazem 24hr Cd | 15 | $677 | $45 |
| Metoprolol | 60 | $346 | $6 |
| Warfarin | 31 | $333 | $11 |
| Sotalol | 37 | $332 | $9 |
| Diltiazem Er | 11 | $294 | $27 |
| Diltiazem | 14 | $249 | $18 |
| Furosemide | 33 | $181 | $5 |
| Atorvastatin | 11 | $164 | $15 |
| Cephalexin | 23 | $136 | $6 |
| Pantoprazole | 14 | $126 | $9 |
| Carvedilol | 13 | $126 | $10 |
| Atenolol | 14 | $105 | $7 |
| Amlodipine Besylate | 12 | $65 | $5 |
2014: 28 drugs
| Multaq | 115 | $53,723 | $467 |
| Xarelto | 54 | $18,997 | $352 |
| Pradaxa | 31 | $15,150 | $489 |
| Tikosyn | 32 | $13,813 | $432 |
| Propafenone Hcl Er | 22 | $10,283 | $467 |
| Enoxaparin | 28 | $10,194 | $364 |
| Flecainide Acetate | 135 | $6,336 | $47 |
| Eliquis | 18 | $5,829 | $324 |
| Amiodarone | 140 | $3,088 | $22 |
| Diltiazem 24hr Er | 62 | $2,031 | $33 |
| Metoprolol | 85 | $1,911 | $22 |
| Cartia Xt | 46 | $989 | $21 |
| Sucralfate | 24 | $953 | $40 |
| Digoxin | 24 | $894 | $37 |
| Diltiazem 12hr Er | 20 | $808 | $40 |
| Digox | 17 | $603 | $35 |
| Diltiazem Er | 18 | $602 | $33 |
| Diltiazem 24hr Cd | 27 | $552 | $20 |
| Metoprolol | 74 | $415 | $6 |
| Warfarin | 43 | $400 | $9 |
| Sotalol | 27 | $360 | $13 |
| Carvedilol | 30 | $305 | $10 |
| Atorvastatin | 12 | $274 | $23 |
| Pantoprazole | 18 | $211 | $12 |
| Diltiazem | 15 | $148 | $10 |
| Cephalexin | 18 | $120 | $7 |
| Atenolol | 20 | $114 | $6 |
| Furosemide | 18 | $80 | $4 |
2013: 28 drugs
| Multaq | 66 | $25,547 | $387 |
| Pradaxa | 41 | $17,719 | $432 |
| Xarelto | 55 | $15,969 | $290 |
| Tikosyn | 33 | $12,574 | $381 |
| Flecainide Acetate | 168 | $8,569 | $51 |
| Propafenone | 15 | $6,604 | $440 |
| Enoxaparin | 15 | $4,456 | $297 |
| Diovan | 14 | $2,815 | $201 |
| Metoprolol | 58 | $1,820 | $31 |
| Diltiazem 24hr Er | 50 | $1,815 | $36 |
| Amiodarone | 117 | $1,583 | $14 |
| Diltiazem 24hr Cd | 39 | $1,430 | $37 |
| Cartia Xt | 39 | $1,411 | $36 |
| Diltiazem Er | 24 | $812 | $34 |
| Sucralfate | 17 | $613 | $36 |
| Sotalol | 29 | $561 | $19 |
| Atorvastatin | 14 | $421 | $30 |
| Warfarin | 35 | $401 | $11 |
| Carvedilol | 31 | $343 | $11 |
| Metoprolol | 55 | $343 | $6 |
| Acebutolol | 11 | $286 | $26 |
| Digox | 35 | $258 | $7 |
| Atenolol | 36 | $163 | $5 |
| Pantoprazole | 13 | $142 | $11 |
| Diltiazem | 14 | $120 | $9 |
| Amlodipine Besylate | 14 | $104 | $7 |
| Lisinopril | 11 | $67 | $6 |
| Furosemide | 11 | $61 | $6 |
Money from drug and device companies
$1,133 in 2025
| 2025 | 3 | 21 | None | $1,133 |
| 2024 | 1 | 1 | None | $6 |
| 2023 | 1 | 1 | None | $23 |
| 2022 | 1 | 1 | None | $14 |
| 2020 | 2 | 6 | None | $369 |
| 2019 | 1 | 1 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | None | $686 | 14 payments
|
| Abbott Laboratories | Aveir | $312 | 6 payments
|
| AstraZeneca UK | None | $135 | 1 payment
|
See all 21 published payments
| Abbott Laboratories | Meals · 2025-12-01 | Aveir | $15 |
| Abbott Laboratories | Meals · 2025-12-01 | Aveir | $36 |
| Abbott Laboratories | Meals · 2025-12-01 | Aveir | $45 |
| Abbott Laboratories | Meals · 2025-12-01 | Aveir | $47 |
| Abbott Laboratories | Travel · 2025-12-01 | Aveir | $160 |
| Abbott Laboratories | Travel · 2025-12-01 | Aveir | $9 |
| AstraZeneca UK | Meals · 2025-11-06 | None | $135 |
| Medtronic | Travel · 2025-04-15 | None | $106 |
| Medtronic | Meals · 2025-04-14 | None | $0 |
| Medtronic | Meals · 2025-04-13 | None | $49 |
| Medtronic | Meals · 2025-04-13 | None | $44 |
| Medtronic | Meals · 2025-04-13 | None | $40 |
| Medtronic | Meals · 2025-04-12 | None | $56 |
| Medtronic | Meals · 2025-04-12 | None | $68 |
| Medtronic | Meals · 2025-04-12 | None | $138 |
| Medtronic | Meals · 2025-04-12 | None | $82 |
| Medtronic | Meals · 2025-04-11 | None | $2 |
| Medtronic | Meals · 2025-04-08 | None | $10 |
| Medtronic | Meals · 2025-04-08 | None | $47 |
| Medtronic | Meals · 2025-04-08 | None | $38 |
| Medtronic | Meals · 2025-04-08 | None | $5 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $6
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
2023: $23
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $23 | 1 payment
|
2022: $14
| Cardiva Medical | Cardiva Vascade 6/7f Vcs | $14 | 1 payment
|
2020: $369
| Medtronic Vascular | None | $336 | 5 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $33 | 1 payment
|
2019: $100
| Amarin Pharma | Vascepa | $100 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1245342708
- Licence
- CA G86914California G86914: Current · expires 2028-08-31
- Trained
- Columbia University College of Physicians and Surgeons, 1983
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-31
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.